Study S000170
A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)
Registration
Registered primary outcomes
- Change in HbA1c [From Baseline to Week 24]
Linked records (4)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0045733 | 1748-P: IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies WENJIAN LIN, Diabetes | 2026 | Other | DOI | cites ClinicalTrials.gov:NCT03798054 |
| R0010585 | iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis. Guo X, Diabetes, obesity & metabolism | 2023 | Randomized trial | PMID 36999231DOI | cites ClinicalTrials.gov:NCT03798054; registry reference DERIVED:36999231 |
| R0013321 | Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Yang W, Diabetes, obesity & metabolism | 2022 | Randomized trial | PMID 35441412DOI | cites ClinicalTrials.gov:NCT03798054; registry reference BACKGROUND:35441412 |
| R0046797 | 850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial YIFAN HE, Diabetes | 2022 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT03798054 |